Foamix Pharmaceuticals (FOMX) & Its Peers Financial Comparison
Foamix Pharmaceuticals (NASDAQ: FOMX) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Foamix Pharmaceuticals to similar businesses based on the strength of its risk, profitability, earnings, valuation, dividends, institutional ownership and analyst recommendations.
This table compares Foamix Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Foamix Pharmaceuticals Competitors||-5,283.42%||-220.58%||-39.49%|
This table compares Foamix Pharmaceuticals and its peers revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Foamix Pharmaceuticals||$5.53 million||-$29.33 million||-3.69|
|Foamix Pharmaceuticals Competitors||$284.49 million||$33.78 million||75.77|
Foamix Pharmaceuticals’ peers have higher revenue and earnings than Foamix Pharmaceuticals. Foamix Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
57.4% of Foamix Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.0% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 17.1% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Volatility & Risk
Foamix Pharmaceuticals has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500. Comparatively, Foamix Pharmaceuticals’ peers have a beta of 2.94, indicating that their average stock price is 194% more volatile than the S&P 500.
This is a breakdown of recent ratings for Foamix Pharmaceuticals and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Foamix Pharmaceuticals Competitors||864||3219||11679||232||2.71|
Foamix Pharmaceuticals presently has a consensus target price of $9.67, suggesting a potential upside of 62.74%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.09%. Given Foamix Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Foamix Pharmaceuticals is more favorable than its peers.
About Foamix Pharmaceuticals
Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions. Its product candidates include FMX101, FMX102, FMX103 and FDX104. Its lead product candidate, FMX101, is a topical foam formulation of the antibiotic minocycline for the treatment of moderate-to-severe acne. FMX102 is a formulation of its minocycline foam being developed for the treatment of impetigo. FMX103 is a topical foam formulation of minocycline for the treatment of moderate-to-severe Papulopustular rosacea. FDX104 is a topical foam formulation of the antibiotic doxycycline for the treatment of severe acne-like rashes induced by chemotherapy. It has conducted one Phase II clinical trial for each of FMX101, FMX102, FMX103 and FDX104.
Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.